Taysha Gene Therapies (NASDAQ:TSHA) CEO Sean Nolan Sells 136,789 Shares of Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CEO Sean Nolan sold 136,789 shares of the company’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the sale, the chief executive officer directly owned 2,949,569 shares in the company, valued at approximately $14,010,452.75. The trade was a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $4.76 on Wednesday. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $6.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. The stock has a market cap of $1.30 billion, a PE ratio of -14.42 and a beta of 1.02. The business has a 50-day simple moving average of $5.09 and a 200-day simple moving average of $4.08.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, equities analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Trending Headlines about Taysha Gene Therapies

Here are the key news stories impacting Taysha Gene Therapies this week:

• Negative Sentiment: CFO Kamran Alam sold 78,968 shares on Jan. 23 at ~$4.75 and 23,849 shares on Jan. 26 at ~$4.61 (total ≈102,817 shares, ≈$485k). This reduced his stake by about 5.11% and 1.62% in the respective filings. CFO Form 4
• Negative Sentiment: CEO Sean P. Nolan sold 136,789 shares on Jan. 23 at ~$4.75 and 41,312 shares on Jan. 26 at ~$4.61 (total ≈178,101 shares, ≈$840k). These sales reduced his ownership by ~4.43% and ~1.40% in the respective filings. CEO Form 4
• Negative Sentiment: Insider Sukumar Nagendran sold 89,132 shares on Jan. 23 at ~$4.75 and 26,918 shares on Jan. 26 at ~$4.61 (total ≈116,050 shares, ≈$547k), reducing his stake by ~6.22% and ~2.00% in the respective filings. Director Form 4

Institutional Trading of Taysha Gene Therapies

Several large investors have recently made changes to their positions in the company. Marex Group plc purchased a new stake in shares of Taysha Gene Therapies during the second quarter worth $29,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies during the second quarter worth about $31,000. ST Germain D J Co. Inc. grew its stake in Taysha Gene Therapies by 81.8% during the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after acquiring an additional 4,333 shares in the last quarter. May Hill Capital LLC acquired a new stake in Taysha Gene Therapies in the 2nd quarter valued at about $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Taysha Gene Therapies in the 3rd quarter valued at about $40,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TSHA has been the topic of several analyst reports. Wells Fargo & Company raised their price target on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. JMP Securities set a $8.00 price target on Taysha Gene Therapies in a research note on Wednesday, November 5th. Citizens Jmp upped their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.67.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.